

### Claims

1. An attenuated Jeryl-Lynn mumps virus strain characterised by the SH gene and the N terminus of the HN gene comprises the nucleic acid sequence as depicted in figure 1.
2. A mumps vaccine comprising a substantially homogenous immunogenic Jeryl-Lynn isolate.
3. A mumps vaccine as claimed in claim 2 comprising a homogenous isolate of claim 1.
4. A combined vaccine comprising a substantially homogenous immunogenic Jeryl-Lynn isolate and one or more of attenuated measles virus, or attenuated rubella virus or killed measles or rubella virus, or subunits of such viruses.
5. A vaccine as claimed in claim 3 or 4 additionally comprising an agent for the protection against varicella or zoster infections.
6. A method of producing a substantially homogenous immunogenic Jeryl-Lynn isolate. the method comprising:  
passaging a Jeryl-Lynn preparation on a suitable cell line.  
Selecting pure culture using the steps of either:  
a) limit dilution; or  
b) individual plaque isolation.
7. A homogeneous immunogenic Jeryl-Lynn isolate for use in medicine.
8. A method of inducing immunity in a mammal susceptible to mumps infection comprising the administration to the mammal of an effective amount of a vaccine according to any of claim 2-5.